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Intrinsically disordered proteins/peptides play a crucial role in many physiological and pathological
events and may assume a precise conformation upon binding to a specific target. Recently, we have
described the conformational and functional properties of two linear ester peptides provided with the
following sequences: Y-G-E-C-P-C-K-OAllyl (PepK) and Y-G-E-C-P-C-E-OAllyl (PepE). Both peptides
are characterized by the presence of the ‘‘CPC’’ motif together with a few amino acids able to promote
disorder. The CPC sequence is a binding motif for the CXCR4 receptor that represents a well-known
target for cancer therapies. In this paper, we report on synthetic amphiphilic peptides that consist of
lipophilic derivatives of PepE and PepK bearing two stearic alkyl chains and/or an ethoxylic spacer.
These peptide amphiphiles form stable supramolecular aggregates; they present conformational features
that are typical of intrinsically disordered molecules as shown by CD spectroscopy. Solution
fluorescence and DLS studies have been performed to evaluate Critical Micellar Concentrations and the
dimension of supramolecular aggregates. Moreover, preliminary in vitro cell-based assays have been
conducted to investigate the molecular recognition processes involving the CXCR4 receptor. In the
end, the results obtained have been compared with the previous data generated by the corresponding
non-amphiphilic peptides (PepE and PepK).
1. Introduction
Peptides may carry out a broad range of biological functions
while acting as growth factors, neurotransmitters, and hormones.1–5
The regulatory role that they may play in physiological tasks has
pushed pharmacologists to exploit peptides as therapeutic6,7 or
diagnostic tools.8,9 Peptide drugs can offer many advantages:
they have specific features but they have a broad spectrum of
activity; they have less side effects than organic molecules; they
allow an infinite array of sequences which could be designed in
order to regulate physiological processes.10 Peptides can act as
agonists or antagonists of biomolecular processes by interacting
with cell surface receptor systems that show over-expression
in several neoplastic and non-neoplastic cells.11 As the CXCR4
receptor is overexpressed in several human cancers, it is con-
sidered one of the most relevant targets in drug discovery. The
blockade of the CXCR4–CXCL12 interaction has been extensively
investigated as a potential research path for new cancer thera-
pies.12 Recently, we have designed and synthesized a CPC motif
containing peptides by using the N-terminal region of CXCL12 as
a template.13
Afterwards, we generated two novel linear ester peptides
containing the following sequences: Y-G-E-C-P-C-K-OAllyl (PepK)
and Y-G-E-C-P-C-E-OAllyl (PepE). Both these peptides are charac-
terized by the presence of the same CPCmotif together with a few
amino acids able to foster disorder.14 For PepE and PepK, NMR
and circular dichroism (CD) spectra have revealed the lack of
well-defined secondary structure elements, thus confirming their
high conformational flexibility. Moreover, molecular dynamics
(MD) simulations have pointed out that PepE and PepK could
dynamically explore conformational ensembles, thanks to the
absence of a regular secondary structure. We have also preliminary
tested the biological properties of these peptides: they have
targeted CXCR4 and they have modulated the adenylate cyclase
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production with remarkable performances, better than the ones
obtained so far by AMD3100 i.e., a known CXCR4 antagonist.
The application of an intrinsically disordered peptide as a
biosensor (or even in molecular recognition) could rely on its
own capability to control the transition between diﬀerent
structural states.15 One opportunity to induce conformational
peptide rearrangement could be achieved by modifying the
bioactive peptide sequence with a hydrophobic moiety. This
modification led to the design of peptide amphiphiles (PAs), a
class of emergent molecules, that, by combining the structural
features of amphiphilic surfactants with the functions of bioactive
peptides,16–18 are useful for biotechnological applications in drug
delivery of pharmacological molecules.19–21 Furthermore, PAs are
able to self-assemble into a wide variety of nanostructures, such as
spherical entities with a cylindrical geometry or rod like micelles,
monolayers, bilayers, vesicles and nanofibers. Supramolecular
aggregation of PAs is driven by the presence of both hydrophilic
and hydrophobic moieties. In detail, the hydrophilic moiety is
composed of a bioactive peptide sequence enriched with hydro-
philic amino acids. In addition, the sequence can be improved by
an ethoxylic linker. The hydrophobic moiety is made of hydro-
carbon groups such as one or two long alkyl chains containing
more than ten carbon atoms.
Taking into account these elements, we have designed
lipophilic derivatives of PepE and PepK bearing two stearic
alkyl chains and/or an ethoxylic spacer. The structural charac-
terization of self-assembled PAs in aqueous solution was assessed
by fluorescence spectroscopy and Dynamic Light Scattering (DLS),
while the conformational preferences were evaluated by CD.
To test the binding properties and the biological behaviour of
peptides, biological assays were also carried out in cells over-
expressing the CXCR4 receptor. Finally, the structural features
revealed by this study were compared with the ones previously
found for disordered linear peptides.
2. Materials and Methods
2.1. Reagents
All Na-Fmoc-amino acid derivatives, 2-chlorotrityl chloride
resin pre-loaded with Fmoc-Glu-OAllyl and Fmoc-Lys-OAllyl
and coupling reagents were purchased from Calbiochem-
Novabiochem (Laufelfingen, Switzerland), Iris Biotech GMBH
(Marktredwitz, Germany) or from Inbios (Napoli, Italy). Fmoc-21-
amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid (Fmoc-Ahoh-OH)
was purchased from Neosystem (Strasbourg, France). N,N-Diocta-
decylsuccinamic acid was synthesized according to the published
methods.22 All other chemicals were commercially available by
Sigma-Aldrich (Milano, Italy) and were used as received unless
otherwise stated.
Preparative RP-HPLC was carried out on a LC8 Shimadzu
HPLC system (Shimadzu Corporation, Kyoto, Japan) equipped
with a UV lambda-Max Model 481 detector using a Phenomenex
(Torrance, CA) C4 (300 Å, 250  21.20 mm, 5 m) column. Elution
solvents are H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B), from
20% to 95% over 20 minutes at 20 mLmin1 flow rate. The purity
and identity of the products were assessed by analytical LC–MS
analyses by using Finnigan Surveyor MSQ single quadrupole
electrospray ionization (Finnigan/Thermo Electron Corporation
San Jose, CA), column C4-Phenomenex eluted with an H2O/0.1%
TFA (A) and CH3CN/0.1% TFA (B) from 20% to 95% over
20 minutes at 0.8 mL min1 flow rate.
2.2. Amphiphilic peptide synthesis
All amphiphilic peptides were synthesized following a solid
phase peptide standard protocol using Fmoc chemistry on
2-chlorotrityl chloride resin pre-loaded (0.24 scale mmol) with
the side chain of a Fmoc-Lys-OAllyl and a Fmoc-Glu-OAllyl,
respectively. The sequence H-YGECPC was built on both resins.
In particular the resins were allowed to swell in dichloro-
methane (DCM) and Fmoc-deprotection steps were performed
by treating the resin for 30 min in a dimethylformamide (DMF)/
Piperidine (Pip) (80/20, v/v) solution.
For coupling steps the resin was suspended in DMF containing
three equivalents of the Fmoc-protected amino acid, O-benzo-
triazole-tetramethyl-uronium-hexafluoro-phosphate (HBTU), and
diisopropylethylamine (DIEA) (6 eq.), and the reaction mixture
was shaken for 2 h at room temperature. The Fmoc ethoxylic
spacer and lipophilic N,N-dioctadecylsuccinic acid were coupled,
as previously described.23
Peptides were cleaved by soaking the resin in TFA/H2O/
triisopropylsilane (TIS) (3.0 mL, 95/2.5/2.5, v/v/v) for 3 h.
Cleavage mixtures were filtered from the resin and crude
products were precipitated by adding cold water, centrifuged,
and decanted. The resulting white solids were dissolved in a
water and acetonitrile 4 : 1 v : v (10 mL) mixture and freeze-dried
to obtain a white powder that was analyzed for purity and
purified by preparative RP-HPLC. Purified peptides were charac-
terized by LC-ESI-MS.Mass values found: 1443 a.m.u. [(C18)2-PepE];
1442 a.m.u. [(C18)2-PepK];1776 a.m.u. [(C18)2-L-PepK]; 1777 a.m.u.
[(C18)2-L-PepE].
2.3. Preparation of aggregate solutions
Samples were prepared by dissolving the lyophilized PAs in
aqueous solutions. In detail, (C18)2-PepK and (C18)2-L-PepK
were dissolved in 10 mM TRIS buﬀer at pH 8.0, whereas
(C18)2-PepE and (C18)2-L-PepE in 10 mM phosphate buﬀer
(PBS) at pH 7.4. The pH-meter was calibrated with three
standards at pH 4.00, pH 7.00 and pH 10.00. In most cases
the samples to be measured were prepared from stock solutions.
The concentrations of all solutions were determined by UV-Vis
absorbance measurements carried out on a Thermo Fisher
Scientific Inc (Wilmington, Delaware USA) Nanodrop 2000c
spectrophotometer equipped with a 1.0 cm quartz cuvette
(Hellma) using a molar absorptivity (e) of 1390 M1 cm1 at
l = 275 nm, which corresponds to the wavelength of the
tyrosine residue.
2.4. Fluorescence measurements
Values of critical micellar concentration (CMC) of peptide
amphiphiles were obtained by fluorescence measurements.
Fluorescence spectra were recorded at room temperature on a
Paper Molecular BioSystems
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 2925--2932 | 2927
Jasco Model FP-750 spectrofluorophotometer (Jasco Int. Co.
Ltd, Tokio, Japan) in a 1.0 cm path length quartz cell. Equal
excitation and emission bandwidths were used throughout
the experiments, with a recording speed of 125 nm min1
and automatic selection of the time constant. CMC values were
measured by using 8-anilino-1-naphthalene sulfonic acid ammo-
nium salt (ANS) as the fluorescent probe.24 Small aliquots of
peptide aqueous solution were added to a fixed volume (1.00 mL)
of 2.0  105 M ANS fluorophore directly in the quartz cell. CMC
values were determined by linear least-squares fitting of the
fluorescence emission at 480 nm, upon excitation at 350 nm
versus the amphiphile concentration. Fluorescence emission
spectra of the tyrosine residue in the PAs were recorded at
5  105 M concentration and 25 1C exciting the peptide
solution at 275 nm.
2.5. Dynamic light scattering characterization
Dynamic light scattering (DLS) measurements were carried out
using a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA)
that employs a 1731 backscatter detector. Other instrumental
settings are measurement position (mm): 4.65; attenuator: 8;
temperature 25 1C; cell: disposable sizing cuvette. DLS samples
were prepared at a final concentration of 2.0 104 M and
centrifuged at room temperature at 13000 rpm for 5 min.
2.6. CD measurements
Far-UV CD spectra were recorded from 260 to 190 nm on a Jasco
J-810 spectropolarimeter equipped with a NesLab RTE111
thermal controller unit using a 1 mm quartz cell at 25 1C. CD
spectroscopy of alkylated derivatives of PepE and PepK was
carried out at 2.0  104 M concentration in 2.0 mM phosphate
buﬀer and 10 mM TRIS, respectively. Other experimental set-
tings were: scan speed, 10 nm min1; sensitivity, 50 mdeg; time
constant, 16 s; bandwidth, 1 nm. Each spectrum was obtained
averaging three scans, and by subtracting contributions from
other species in solution and converting the signal to mean
residue ellipticity in units of deg cm2 dmol1 res1.
2.7. Biological test
The binding between CXCR4 and the four peptides was evaluated
as previously described.25 Briefly 2.5  105 CCRF–CEM cells were
pre-incubated with 10 mM antagonist peptides in binding buffer
(PBS 1 plus 0.2% BSA and 0.1% NaN3) for 1h at 37 1C, 5% CO2
and then labeled for 45 minutes with an anti-CXCR4 PE-antibody
(FAB170P, clone 12G5, R&D Systems, Minneapolis, MN, USA).
Cells were washed in PBS and analyzed using an FACS Canto II
cytofluorimeter (Becton Dickinson Immunocytometry Systems,
Mountain View, CA, USA). CCRF-CEM cell migration was assayed
in 24-well Transwell chambers (Corning Inc., Corning, NY) using
inserts with an 8 mm pore membrane. Membranes were pre-
coated with collagen (human collagen type I/III) and fibronectin
(20 mg mL1 each). CCRF-CEM cells were placed in the upper
chamber (1  105 cells per well) in RPMI containing 1% BSA
(migration media). Cells were pre-incubated for 45 min with the
CXCR4 antagonist and allowed to migrate toward 100 ng mL1
CXCL12 in the lower chamber. After 16 h incubation, migrated
cells were collected from the lower chamber and counted. The
migration index was defined as the ratio between migrating
cells in the experimental group and migrated cells in the
control group.
We have conducted c-AMP–assay by using CCRF-CEM cells
(1  106) that were incubated in the presence of four peptides
or Plerixafor (known as AMD3100: a CXCR4 antagonist) that
has provided proof of concept for inhibition of the CXCR4
pathway26 at two different concentrations (1 and 10 mM) in
combination with forskolin (F) (1 mM) for 20 min, followed by
stimulation with CXCL12 (100 ng mL1) for 10 min. Controls
include cells stimulated with CXCL12 and forskolin or forskolin
alone in the absence of anti-CXCR4 inhibitors. Cells have been
harvested and lysed with 0.1 M HCl and cAMP levels have been
assayed by a direct competitive enzyme immunoassay (BioVision
Incorporated) according to manufacture instructions.
3. Results and discussion
3.1. Design and synthesis
Recently we synthesized two linear intrinsically disordered
peptides, PepK and PepE, based on the same sequence (YGECPC).
This sequence was designed choosing amino acids with disorder
propensity.14 Subsequently, PepK and PepE were obtained by
adding one charged residue at the C-terminus. In the case of
PepK the charged residue was lysine, whilst PepE was provided
with glutamic acid. The charged amino acids, namely Lys and
Glu, were introduced in order to evaluate the influence of
negative and positive charges on the aggregation of short
sequence structures. Peptide amphiphiles, (C18)2-PepK and
(C18)2-PepE, reported in Fig. 1 were obtained by conjugating
two aliphatic chains of eighteen carbon atoms at the N-terminus
of both sequences. Two other PA derivatives, indicated in Fig. 1
as (C18)2-L-PepK and (C18)2-L-PepE, were obtained by inserting
the AhOh exoethylene linker between the peptide sequence
and the hydrophobic double-tail. This linker, the same for both
peptides, allows us to increase the hydrophilicity of PAs without
modifying their final charge, in this way avoiding intra- and
inter-electrostatic interactions. Indeed, the insertion of the
Fig. 1 Schematic representation of (C18)2-PepK, (C18)2-PepE and
(C18)2-L-PepK and (C18)2-L-PepE. The peptide sequences are reported
using the one-letter amino acid code.
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linker leads to the distancing between the bioactive peptide and
the hydrophobic shell of the aggregates. The relatively short
length of this moiety was chosen in order to avoid possible
formation of a hydrophilic pocket, able to hide the amino acid
sequences. Finally, as is well-known from the literature,27 the
presence of PEG chains can increase the in vivo blood circula-
tion of self-assembled PA aggregates. PAs were synthesized
according to standard solid phase peptide synthesis protocols
using 2-Cl-(Trt)-Cl preloaded resin as a polymeric support. The
ethoxylic moiety and the two alkyl chains at the N-terminus of
both peptide sequences were added as previously reported.23
After RP-HPLC purification, the products were identified by
ESI-MS spectrometry.
3.2. Aggregate preparation and structural characterization
Supramolecular aggregates of pure PA derivatives were obtained
by dissolving the lipophilic derivatives in 10 mM phosphate
buﬀer (pH 7.4) for PepE and in 10 mM TRIS buﬀer (pH 8.0) for
PepK. The choice of buﬀers to be used for solubilizing monomers
was imposed by their diﬀerent propensities to aggregate. In fact,
according to the pKa values of glutamic acid and lysine residues,
all PAs have shown a net charge in a neutral or slightly basic water
solution: negative in PepE and positive in PepK. Self-aggregation
properties of the amphiphilic peptides were investigated by
fluorescence spectroscopy and DLS.
Critical micellar concentration (CMC) values were estimated
by fluorescence spectroscopy by using ANS as a fluorescent
probe. The fluorescence intensity of ANS depends on the
surrounding environment. The ANS fluorophore emits only in
a hydrophobic environment such as the hydrophobic core of a
micellar aggregate, whereas it does not emit in water solution.
CMC values can be estimated according to the data provided by
the graphical break-point, reported in Fig. 2. These data have
been obtained by plotting the fluorescence intensity of ANS in
the emission maximum at 470 nm, as a function of the PA
derivative concentration. Table 1 displays CMC values: 7.0 
106 mol kg1 for (C18)2-PepK and 1.9  105 mol kg1 for
(C18)2-L-PepK. These values indicate that the introduction of
the ethoxylic linker slightly aﬀects the formation of aggregates
capable of capturing the ANS, but they also confirm the high
stability of both the resulting aggregates. Furthermore, these
values comply with those previously found for peptide amphi-
philes containing the same hydrophobic moiety.28,29 Nonetheless,
the CMC values of both the amphiphilic derivatives of PepE are
higher than the corresponding ones for PepK. This behaviour
indicates that PepE owns a lower propensity to aggregate if
compared to PepK; this may depend on the diﬀerent inter-
action of the charges with the buﬀer salts. Data obtained by the
DLS for all compounds are summarized in Table 1: the hydro-
dynamic radii, RH; the diﬀusion coeﬃcients, D; and the poly-
dispersity indices, PDI. Measurements were performed at
y = 1731 on self-assembled PAs at a concentration of 2 
104 mol kg1 in the previously reported buﬀer solution. All
aggregate solutions show a monomodal distribution, which
indicates the presence of just one population of aggregates.
At infinite dilution, RH values can be examined by using
translational diﬀusion coeﬃcients in the Stokes–Einstein equation.
An increase of the radius of 20% was observed for (C18)2-PepE
(100 nm) with respect to (C18)2-PepK (80 nm) (see Fig. 3). Whereas
only a slight difference in radii can be detected for the derivatives
containing the spacer. Fluorescence measurements were carried
out by exciting buffer solutions at 275 nm aiming to evaluate shifts
of tyrosine fluorophore emission as a consequence of aromatic
quenching on the surface of the aggregates. In Fig. 4 (upper panel)
Fig. 2 Fluorescence intensity of the ANS fluorophore at 470 nm as a
function of PAs [(C18)2-L-PepK (A) and (C18)2-PepK (B)] concentration;
data are multiplied by a scale factor for a better comparison. CMC values
are established from graphical break points.
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emission spectra for different PepE derivatives are reported. The
behaviour of tyrosine does not show significant differences in
intensity or in the wavelength shift. These results seem to exclude
interaction among peptide side chains on the surfaces of aggre-
gates. Similar results have been obtained for PepK derivatives
(Fig. 4 lower panel).
3.3. Circular dichroism measurement
Conformational behaviours of PepE and PepK amphiphiles
were investigated by CD spectroscopy. Lyophilized peptides
were dissolved in the suitable weakly basic buﬀer (TRIS or PBS,
see experimental section) at 2  104 M concentration. Under
these experimental conditions, PAs are well above the CMC
concentrations that have been determined by fluorescence and
the presence of supramolecular aggregates in aqueous solution is
fostered. In Fig. 5 the CD spectra of PepE (panel A) and PepK
(panel B) derivatives are reported. The corresponding conforma-
tional preferences for all peptides were also analyzed by the
CAPITO web-server.30 The CD spectrum of (C18)2-PepE does not
show any propensity to fold as indicated by CD spectra, present-
ing a negative minimum at around 198 nm, typical for unordered
structures. Moreover, the presence of the ethoxylic spacer does
not influence significantly the dichroic bent of the PA. This trend
was also confirmed by CAPITO analysis30 (data not shown).
Furthermore, two weak maxima at 208 and 232 nm are also
detectable in the CD spectra of PepK derivatives (see Fig. 5B), in
addition to the minimum at 196 nm. These spectra suggest that
the replacement of the glutamic acid with the lysine at the
C-terminus induces a rearrangement of the secondary structure
with a partial folding of the IDP.
Further attempts to validate the CD results with more precise
comparative conformational studies by NMR spectroscopy were
Table 1 Structural parameters for the aggregates obtained from fluores-
cence measurements (critical micellar concentration values) and dynamic
light scattering measurements (diﬀusion coeﬃcients, D, hydrodynamic
radii, RH, and polydispersity indices)
Systems CMC (mol kg1) RH (nm) D  1012 (m2 s1) PDI
(C18)2-PepK 7.0  106 80  27 3.1  1.0 0.270
(C18)2-L-PepK 1.9  105 82  34 3.1  1.5 0.182
(C18)2-PepE 3.9  105 112  44 1.9  0.7 0.264
(C18)2-L-PepE 3.2  105 101  39 2.4  0.5 0.226
Fig. 3 DLS profiles of (C18)2-PepK (A) and (C18)2-PepE (B) peptide
amphiphiles at a concentration of 2  104 M.
Fig. 4 Fluorescence emission spectra recorded by exciting buﬀer solutions
at 275 nm for PepE derivatives (up) and PepK derivatives (down).
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hampered by the high aggregation levels of PepE and PepK
derivatives. Indeed, this aggregation produced sample precipita-
tion and/or complete disappearance of signals in 1D [1H] and 2D
[1H, 1H] NMR spectra; this made impossible the process of
resonance assignments.
3.4. Functional characterization: peptide eﬀects on the
CXCR4 receptor pathway
Then, the peptides (C18)2-PepK, (C18)2-L-PepK, (C18)2-PepE,
and (C18)2-L-PepE, have been tested in order to determine:
Fig. 5 CD spectra of: (A) (C18)2-PepE and (C18)2-L-PepE; and (B) (C18)2-PepK and (C18)2-L-PepK.
Fig. 6 Comparison of cAMP modulation by PepE, PepK, (C18)2-PepE, (C18)2-L-PepE, (C18)2-PepK and (C18)2-L-PepK and AMD3100 at 1 mM
and 10 mM.
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(i) peptide binding to the receptor through an indirect binding
assay; (ii) the inhibition of CXCL12-induced migration;
(iii) cAMP levels. The results were compared to the ones for
AMD3100 that is the lead CXCR4 antagonist.26 The binding of
the four peptides to CXCR4 was evaluated in CCRF-CEM using a
CXCR4 12G5 monoclonal antibody as previously described,31
and two concentrations (1 mM and 10 mM) which are matching
the ones previously used in CXCR4 binding assays.
The four peptides did not displace 12G5 antibody compared
to AMD3100, which strongly reduced antibody binding to
CXCR4. These behaviours agree with those previously obtained
for the free PepE and PepK peptides.14 This could be explained
considering the diﬀerent binding sites on AMD3100/12G5 anti-
body and the four highly flexible and disordered peptides. Also,
a migration assay was performed and the four peptides resulted
to reduce the migration of CCRF-CEM cells towards CXCL12 even
if they showed less activity than AMD3100 (data not shown).
Taking into account that CXCR4 is a G-Protein coupled
receptor, it inhibits through the G-protein the adenylate cyclase
activity and fosters the cAMP production as ‘‘second messen-
ger’’.25 As a result of the binding to CXCL12, we also evaluated
the cAMP levels after treatment with the four peptides. The
results indicate that in the presence of CXCL12 (100 ng mL1)
and Forskolin (1 mM): (i) (C18)2-PepK, (C18)2-L-PepK, (C18)2-PepE,
and (C18)2-L-PepE show a dose dependent increase of the cAMP
level of about 66% at the lower dose (1 mM) and of 84% at the
higher dose (10 mM); (ii) at 10 mM, (C18)2-L-PepK increases cAMP
levels up to 93% and (C18)2-PepE increases the cAMP level to 95%;
(iii) AMD3100 exhibits less eﬃcient activities on the adenylate
cyclase when compared to the four peptides (Fig. 6).
4. Conclusions
We have explored the possibility that intrinsically disordered
peptides could be used as polar heads connected to alkyl chains
to generate new molecular buildings for drug delivery vehicles
in cells over-expressing the CXCR4 receptor. In our previous
investigations, two peptides were synthesized and studied by
NMR and CD spectroscopy.32 These compounds were indicated
as PepE and PepK due to the presence of a glutamic acid or a
lysine residue at the C-terminus. The absence of regular secondary
structure elements confirmed the natively disordered nature of
these peptides.
In the present study, we have investigated the opportunity
to induce conformational rearrangement by modifying these
peptide sequences with two alkyl chains of eighteen carbon
atoms each and with an ethoxylic linker. In fact, the insertion
on peptides of aliphatic moieties pushes the resulting amphi-
philic molecules to self-assemble in supramolecular aggregates.
Once confined on the external surface of the aggregates, peptides
could undergo a disorder-to-order transition.32 As demonstrated
by fluorescence and DLS studies, all the designed PAs are able to
self-assemble in large aggregates with an average diameter ranging
between 80 and 110 nm, independently from their charge and from
the presence of the PEG spacer.
All four PAs are strongly aggregated and poorly soluble
at high concentrations (0.50–1.0 mM). These characteristics
made them unsuitable for characterization performed by
means of solution NMR techniques; even after changing the
experimental conditions such as implementing buffers at
different pH and temperatures.
CMC values comply with those previously found for peptide
amphiphiles containing the same hydrophobic moiety and they
point out the high stability of the aggregates.28,29 The higher
CMC values of (C18)2-PepE and (C18)2-L-PepE indicate a lower
propensity to aggregate if compared with the corresponding
PepK derivatives. Also after the insertion of the hydrophobic
portion, PepE keeps its tendency towards the disordered/
unfolded state from the conformational point of view. Whereas
both the PepK derivatives show a partial folding, with respect to
the free peptide sequence. To the best of our knowledge, these
compounds are the first CPC motif containing amphiphilic
peptides which are able to aggregate. Comparing the four
peptide derivatives with previously studied PepE and PepK
sequences14, we can point out that (i) all peptides did not show
an evident binding aﬃnity for CXCR4; (ii) the best result about
the migration assay was obtained for PepE sequences; and
(iii) the highest cAMP percentages were obtained for (C18)2-L-
PepE- (93%) and (C18)2-L-PepK (95%) at 10 mM (Fig. 6).
According to these preliminary results, these PA systems
could be further modified to realize new supramolecular
peptide-based compounds, able to be encapsulated by living
cells for biomedical industrial application.
Abbreviations
AhOh 21-Amino-4,7,10,13,16,19-hexaoxaheneicosanoic
acid
ANS 8-Anilino-1-naphthalene sulfonic acid ammonium
salt
CMC Critical micellar concentration
cAMP Cyclic adenosine monophosphate
CD Circular dichroism
DCM Dichloromethane
DIEA N,N-Diisopropylethylamine
DLS Dynamic light scattering
DMF N,N-Dimethylformamide
DPC n-Dodecyl phosphatidylcholine
EDTA Ethylenediaminetetraacetic acid
Fmoc 9-Fluorenylmethoxycarbonyl
G-CSF Granulocyte-colony stimulating factor
GTP Guanine nucleotide triphosphate
HBTU O-benzotriazole-tetramethyl-uronium-hexafluoro-
phosphate
IDP Intrinsically disordered protein or peptide
MD Molecular dynamics
PAs Peptide amphiphiles
PBS Phosphate buﬀer
RP-HPLC Reverse-phase high-pressure liquid chromatography
SPPS Solid phase peptide synthesis
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TFA Trifluoroacetic acid
TIS Triisopropylsilane
TRIS buﬀer Tris(hydroxymethyl)aminomethane
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